Notably, HyT 3a (54) effectively induced PARP1 degradation in BRCA-mutant breast cancer and TNBC cells, achieving approximately 60% PARP1 degradation in MDA-MB-231 cells at 2.5 μM over 48 h, exhibiting superior antitumor efficacy compared to olaparib (Fig. 26). The gene discussed is PARP1; the disease is breast carcinoma.